The Japanese government on March 7 announced new NHI prices for the FY2025 drug price revision, effective April 1. With…
HOME > ARCHIVE
ARCHIVE
- Pharmaceutical Industry Salary Survey 2011
December 26, 2011
- AFII Grants France-Japan Investment Award to sanofi-aventis, Canon
December 19, 2011
- Plan Like Your Life Depended on It… It Just Might!
December 5, 2011
- Interviewing and Hiring: Strong Character Plus Good Attitude Equals Great Potential
November 14, 2011
- A Cry from the Next Generation of Japanese Pharmaceutical Executives
October 24, 2011
- The Art of Business
September 26, 2011
- NBI Increasing Efforts to Ensure Proper Use of Prazaxa
August 29, 2011
- Remicade Obtains Approval for Partial Changes in Dosage for Crohn's Disease
August 29, 2011
- Mitsubishi Chemical Medience Begins Contract Synthesis of Radiolabeled Compounds
August 29, 2011
- Emerging Markets, Japan Drove Growth in 1st Half of 2011 for Global Megapharmas
August 29, 2011
- Hisamitsu to Apply for Transdermal Oxybutynin for OAB in FY2012
August 29, 2011
- Seikagaku to Conduct Add'l Clinical Trial for SI-6603 in Japan
August 29, 2011
- Drug Wholesalers' Operating Profit Rate at Record Low 0.13% in FY2010: JPWA
August 29, 2011
- Chugai Files Application for Add'l Indication for Kytril Based on Data in Public Domain
August 29, 2011
- Kyowa Kirin Initiates PIII Trial of ARQ197 for NSCLC in Asian Countries
August 29, 2011
- Teijin Pharma, Astellas Sign New Marketing Agreement on Febuxostat
August 29, 2011
- Astellas, Kyowa Kirin Apply for Higher Doses of Amoxicillin Based on Data in Public Domain
August 29, 2011
- AnGes MG Granted Pharmaceutical Use Patent for Ets-1 in US
August 29, 2011
- Chugai Licenses Melanoma Treatment Vemurafenib from Roche; PI Trial to Begin in 2012
August 29, 2011
- Pfizer Japan Withdraws NDA for Fesoterodine
August 29, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…